Loading...
XNASOPRX
Market cap98mUSD
Jan 10, Last price  
5.36USD
1D
-0.92%
1Q
-19.16%
Jan 2017
120.58%
IPO
32.35%
Name

OPTIMIZERx Corp

Chart & Performance

D1W1MN
XNAS:OPRX chart
P/E
P/S
1.38
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
7.62%
Rev. gr., 5y
27.52%
Revenues
72m
+14.53%
100,31883,68626,72371,0651,111,5202,048,6994,957,0166,502,9627,220,6787,751,46212,127,42221,206,36324,598,27443,313,32361,292,59862,450,15671,521,506
Net income
-18m
L+65.93%
-361,466-4,248,853-4,555,689-2,009,024-2,120,762-363,976215,847-1,025,393-595,140-1,539,203-2,104,029226,344-3,142,576-2,383,740273,929-10,586,142-17,565,866
CFO
-7m
L
-303,633-919,402-1,769,562-1,311,413-521,509-624,0331,132,628-56,350515,110-465,965-1,479,831792,555-1,660,796-6,310,386726,03910,654,078-7,239,153
Earnings
Mar 26, 2025

Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
IPO date
May 18, 2005
Employees
109
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
71,522
14.53%
62,450
1.89%
Cost of revenue
82,342
72,719
Unusual Expense (Income)
NOPBT
(10,820)
(10,269)
NOPBT Margin
Operating Taxes
(7,598)
(852)
Tax Rate
NOPAT
(3,222)
(9,416)
Net income
(17,566)
65.93%
(10,586)
-3,964.56%
Dividends
Dividend yield
Proceeds from repurchase of equity
(7,800)
70,651,512
BB yield
3.18%
-23,647.37%
Debt
Debt current
2,222
90
Long-term debt
35,195
379
Deferred revenue
Other long-term liabilities
Net debt
23,564
(73,672)
Cash flow
Cash from operating activities
(7,239)
10,654
CAPEX
(87)
(245)
Cash from investing activities
(25,337)
(58,176)
Cash from financing activities
28,220
(18,951)
FCF
(11,856)
(4,293)
Balance
Cash
13,852
74,141
Long term investments
Excess cash
10,276
71,018
Stockholders' equity
(64,238)
(46,674)
Invested Capital
227,615
173,019
ROIC
ROCE
EV
Common stock shares outstanding
17,125
17,784
Price
14.31
-14.82%
16.80
-72.95%
Market cap
245,056
-17.98%
298,771
-72.81%
EV
268,620
225,099
EBITDA
(8,419)
(8,247)
EV/EBITDA
Interest
1,454
852
Interest/NOPBT